Osteoclast-targeted delivery of anti-miRNA oligonucleotides by red blood cell extracellular vesicles.

[1]  Hao Zhang,et al.  Cell-derived nanovesicle-mediated drug delivery to the brain: Principles and strategies for vesicle engineering , 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  Hongji Yan,et al.  A novel nano delivery system targeting different stages of osteoclasts. , 2022, Biomaterials science.

[3]  Heng Yin,et al.  MYC-mediated miR-320a affects receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclast formation by regulating phosphatase and tensin homolog (PTEN) , 2021, Bioengineered.

[4]  Xiaozhong Zhou,et al.  Cytokine-scavenging nanodecoys reconstruct osteoclast/osteoblast balance toward the treatment of postmenopausal osteoporosis , 2021, Science advances.

[5]  Xiangyin Kong,et al.  CST6 protein and peptides inhibit breast cancer bone metastasis by suppressing CTSB activity and osteoclastogenesis , 2021, Theranostics.

[6]  Hiroyuki Takahashi,et al.  Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer , 2021, Nature Communications.

[7]  M. Benito,et al.  Osteoporosis Remission and New Bone Formation with Mesoporous Silica Nanoparticles , 2021, Advanced science.

[8]  M. Beksac,et al.  CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma , 2021, Molecular Cancer.

[9]  X. Nguyen,et al.  Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery , 2021, Journal of extracellular vesicles.

[10]  Lijuan Duan,et al.  Blood cell-derived extracellular vesicles: diagnostic biomarkers and smart delivery systems , 2021, Bioengineered.

[11]  Li Duan,et al.  Engineering exosomes for targeted drug delivery , 2021, Theranostics.

[12]  Yin Xiao,et al.  Exosome-mediated delivery of gene vectors for gene therapy. , 2020, Nanoscale.

[13]  Hong Yuan,et al.  Water/pH dual responsive in situ calcium supplement collaborates simvastatin for osteoblast promotion mediated osteoporosis therapy via oral medication. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Murad Alahdal,et al.  Exosome-mediated drug delivery for cell-free therapy of osteoarthritis. , 2020, Current medicinal chemistry.

[15]  Li Duan,et al.  Exosome-mediated delivery of kartogenin for chondrogenesis of synovial fluid-derived mesenchymal stem cells and cartilage regeneration. , 2020, Biomaterials.

[16]  D. Monroe,et al.  miRNAs in Osteoclast Biology. , 2020, Bone.

[17]  Boris Fehse,et al.  Overcoming the delivery problem for therapeutic genome editing: Current status and perspective of non-viral methods. , 2020, Biomaterials.

[18]  Li Duan,et al.  Chondrocyte-Targeted MicroRNA Delivery by Engineered Exosomes toward a Cell-Free Osteoarthritis Therapy. , 2020, ACS applied materials & interfaces.

[19]  H. D. del Portillo,et al.  Extracellular Vesicles Derived from Plasmodium-infected and Non-infected Red Blood Cells as Targeted Drug Delivery Vehicles. , 2020, International journal of pharmaceutics.

[20]  C. Théry,et al.  SnapShot: Extracellular Vesicles , 2020, Cell.

[21]  Xuejuan Gao,et al.  Cytoplasmic PCNA is located in the actin belt and involved in osteoclast differentiation , 2020, Aging.

[22]  Haiqiang Jin,et al.  The role of extracellular vesicles from stored RBC units in B lymphocyte survival and plasma cell differentiation , 2020, Journal of leukocyte biology.

[23]  Zhousheng Xiao,et al.  Osteoporosis: Mechanism, Molecular Target, and Current Status on Drug Development. , 2020, Current medicinal chemistry.

[24]  Yasuhiro Kobayashi,et al.  The Regulation of Bone Metabolism and Disorders by Wnt Signaling , 2019, International journal of molecular sciences.

[25]  G. Banfi,et al.  Perspectives on miRNAs as Epigenetic Markers in Osteoporosis and Bone Fracture Risk: A Step Forward in Personalized Diagnosis , 2019, Front. Genet..

[26]  Q. Guo,et al.  AAV-Anti-miR-214 Prevents Collapse of the Femoral Head in Osteonecrosis by Regulating Osteoblast and Osteoclast Activities , 2019, Molecular therapy. Nucleic acids.

[27]  E. Nabih,et al.  Insight into the possible role of miR‐214 in primary osteoporosis via osterix , 2019, Journal of cellular biochemistry.

[28]  R. Baron,et al.  Sfrp4 repression of the Ror2/Jnk cascade in osteoclasts protects cortical bone from excessive endosteal resorption , 2019, Proceedings of the National Academy of Sciences.

[29]  S. Khosla,et al.  Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways , 2019, Journal of Bone and Mineral Research.

[30]  B. Huo,et al.  Migration and differentiation of osteoclast precursors under gradient fluid shear stress , 2019, Biomechanics and Modeling in Mechanobiology.

[31]  B. Huo,et al.  Gradient fluid shear stress regulates migration of osteoclast precursors , 2019, Cell adhesion & migration.

[32]  W. Leslie,et al.  Osteoporosis , 1996, The Lancet.

[33]  Wafaa R. Mohamed,et al.  Paroxetine and rivastigmine mitigates adjuvant‐induced rheumatoid arthritis in rats: Impact on oxidative stress, apoptosis and RANKL/OPG signals , 2018, Life sciences.

[34]  Jiake Xu,et al.  MiR‐214 is an important regulator of the musculoskeletal metabolism and disease , 2018, Journal of cellular physiology.

[35]  Mengsu Yang,et al.  Efficient RNA drug delivery using red blood cell extracellular vesicles , 2018, Nature Communications.

[36]  H. Moulton,et al.  Anchor peptide captures, targets, and loads exosomes of diverse origins for diagnostics and therapy , 2018, Science Translational Medicine.

[37]  Honglin Jin,et al.  Methotrexate-Loaded Extracellular Vesicles Functionalized with Therapeutic and Targeted Peptides for the Treatment of Glioblastoma Multiforme. , 2018, ACS applied materials & interfaces.

[38]  Janette D Lie,et al.  Osteoporosis: A Review of Treatment Options. , 2018, P & T : a peer-reviewed journal for formulary management.

[39]  Xing Chen,et al.  Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review , 2017, Front. Med..

[40]  Eugenia G. Giannopoulou,et al.  MYC-dependent oxidative metabolism regulates osteoclastogenesis via nuclear receptor ERR&agr; , 2017, The Journal of clinical investigation.

[41]  Liang Wang,et al.  Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity , 2016, Cell Discovery.

[42]  Xiaojuan He,et al.  Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation , 2016, Nature Communications.

[43]  R. Milo,et al.  Revised Estimates for the Number of Human and Bacteria Cells in the Body , 2016, bioRxiv.

[44]  Daniel G. Anderson,et al.  Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. , 2015, Nano letters.

[45]  Jiang Peng,et al.  miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway , 2015, RNA biology.

[46]  Thomas J. Anchordoquy,et al.  Surface Functionalization of Exosomes Using Click Chemistry , 2014, Bioconjugate chemistry.

[47]  Harvey F Lodish,et al.  Engineered red blood cells as carriers for systemic delivery of a wide array of functional probes , 2014, Proceedings of the National Academy of Sciences.

[48]  Shiquan Wu,et al.  Exosomes from red blood cell units bind to monocytes and induce proinflammatory cytokines, boosting T-cell responses in vitro. , 2014, Blood.

[49]  B. Boyce.  Advances in the Regulation of Osteoclasts and Osteoclast Functions , 2013, Journal of dental research.

[50]  Bo Zhou,et al.  MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN , 2013, Cancer Cell International.

[51]  T. Paíno,et al.  Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication , 2013, Haematologica.

[52]  Xiaogang Wang,et al.  miR-214 targets ATF4 to inhibit bone formation , 2012, Nature Medicine.

[53]  Jean X. Jiang,et al.  Gap junctions and hemichannels in signal transmission, function and development of bone. , 2012, Biochimica et biophysica acta.

[54]  L. Ivashkiv,et al.  Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors , 2011, Arthritis research & therapy.

[55]  M. Barbacid,et al.  Cdk2 suppresses cellular senescence induced by the c-myc oncogene , 2010, Nature Cell Biology.

[56]  T. Martin,et al.  Molecular mechanisms in coupling of bone formation to resorption. , 2009, Critical reviews in eukaryotic gene expression.

[57]  P. Sung,et al.  Mechanism of eukaryotic homologous recombination. , 2008, Annual review of biochemistry.

[58]  J. Lorenzo.  Osteoclast precursor cells. , 2007, Advances in experimental medicine and biology.

[59]  Hong-Hee Kim,et al.  Sphingosine 1‐phosphate as a regulator of osteoclast differentiation and osteoclast–osteoblast coupling , 2006, The EMBO journal.

[60]  E. Schwarz,et al.  Osteoclast precursors, RANKL/RANK, and immunology , 2005, Immunological reviews.

[61]  Hans Clevers,et al.  Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. , 2005, Developmental cell.

[62]  E. Schwarz,et al.  Use of a Phage Display Technique to Identify Potential Osteoblast Binding Sites Within Osteoclast Lacunae , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[63]  S. Ejiri,et al.  The preosteoclast and its cytodifferentiation into the osteoclast: ultrastructural and histochemical studies of rat fetal parietal bone. , 1983, Archivum histologicum Japonicum = Nihon soshikigaku kiroku.